Back to results
US 12,180,244 B2Granted
(Thio)nicotinamide ribofuranoside salts and compositions, methods of making, and uses thereof
AssigneeBiosynth AG
InventorsUrs Spitz, Günter Schabert, Aysel Soydemir, Lukas Wick
Life of this patent
Estimating the term…
Abstract
The present invention relates to crystalline (thio)nicotinamide ribofuranoside salts, methods of making such crystalline salts, a pharmaceutical composition comprising same, and use of said crystalline salts as nutritional (dietary) supplements. Furthermore, the present invention relates to a composition comprising amorphous (thio)nicotinamide ribofuranoside salts and its use as nutritional (dietary) supplement.
Claims2
A crystalline nicotinamide-2,3,5-tri-O-acetyl-β-D-ribofuranoside bromide of formula O-Va:
- wherein R is acetyl, characterized by a powder X-ray diffraction pattern substantially as defined in FIG. 1;
- or
- a crystalline nicotinamide-β-D-ribofuranoside bromide of formula O-Ia:
- characterized by a powder X-ray diffraction pattern substantially as defined in FIG. 2;
- or
- a crystalline nicotinamide-β-D-ribofuranoside chloride of formula O-Ib:
- characterized by a powder X-ray diffraction pattern as defined in FIG. 4;
- or
- a crystalline thionicotinamide-2,3,5-tri-O-acetyl-β-D-ribofuranoside bromide of formula S-Va:
- wherein R is acetyl, characterized by a powder X-ray diffraction pattern substantially as defined in FIG. 5;
- or
- a crystalline thionicotinamide-β-D-ribofuranoside bromide of formula S-Ia:
- characterized by a powder X-ray diffraction pattern substantially as defined in FIG. 6;
- or
- a crystalline thionicotinamide-β-D-ribofuranoside chloride of formula S-Ib:
- characterized by a powder X-ray diffraction pattern substantially as defined in FIG. 7;
- or
- a crystalline thionicotinamide-2,3,5-tri-O-acetyl-β-D-ribofuranoside chloride of formula S-Vb:
- wherein R is acetyl, characterized by a powder X-ray diffraction pattern substantially as defined in FIG. 8.
16 more elements
Dependencies are inferred from the claim text.